Related by context. All words. (Click for frequent words.) 69 HCV RESPOND 2 68 R# #mg BID 67 HCV SPRINT 66 BRIM3 66 Grouped Hockey 66 RECORD1 66 Relapsed Multiple Myeloma 66 Wrestling Wrap Up 65 achieved CCyR 65 Nymox NX 65 SVR# 65 CAMMS# 64 relapsed MM 64 AVERROES 64 Clinical Outcomes Utilizing Revascularization 64 Newly Diagnosed Multiple Myeloma 64 subanalysis 64 PreCISe 64 Shows Promising 63 Placebo Controlled Trial 63 #rd Annual CTRC 63 prospective multicentre 63 Phase III AFFIRM 63 Pharmacokinetic parameters 63 GOUT 63 mcg albinterferon alfa 2b 63 DASISION 63 Oral Fingolimod 63 Randomized Phase 63 PCI ExTRACT TIMI 63 desvenlafaxine succinate 63 Pooled Analysis 63 phase IIb study 63 TRANSFORMS 63 HBeAg negative patients 63 ACR# ACR# 63 Shows Efficacy 62 Pharmacokinetic PK 62 Combination REOLYSIN R 62 EURIDIS 62 HORIZONS AMI trial 62 Tumor Response 62 CIMZIA TM certolizumab pegol 62 Phase 2b Clinical Trial 62 OPT CHF 62 Post hoc 62 Gastrointestinal Stromal Tumors 62 Immunogenicity 62 Pharmacodynamic 62 Double Blind Randomized 62 Acute Ischemic Stroke 62 NSABP B 62 Long Term Efficacy 62 SuperMedia specializes 62 Pharmacokinetic Study 62 bepotastine besilate nasal spray 62 BARACLUDE R 62 Kaplan Meier analysis 62 oral rivaroxaban 62 REVIVE TA 61 Randomized Double Blind 61 antiretroviral naïve 61 cEVR 61 Relapsing Multiple Sclerosis 61 Screening Trial 61 CLARITY study 61 ExTRACT TIMI 61 azilsartan medoxomil 61 multicenter multinational 61 Relapsing Remitting Multiple Sclerosis 61 Prolongs Survival 61 BOLDER II 61 KRAS status 61 Phase 2b Study 61 ACUITY trial 61 Severe Sepsis 61 Randomized Double blind 61 ACTEMRA TM 61 Demonstrate Significant 61 worsening thrombocytopenia 61 RE LY ® 61 phase IIIb 61 Histologic 61 ICON7 61 Pharmacokinetics PK 61 Folfox 61 #th Annual Interscience 61 STRIDE PD 61 #mg dose [002] 61 BRIM2 61 galiximab 61 unfractionated heparin UFH 61 Val HeFT 61 Prostate AdenoCarcinoma Treatment 61 Randomized Phase II 61 CHAMPION PCI 60 See CLINICAL PHARMACOLOGY 60 Platelet Inhibition 60 trials RCTs 60 Brentuximab Vedotin SGN 60 angiographic outcomes 60 Subgroup analysis 60 JAK Inhibitor 60 APPRAISE 60 ACR# responses 60 iPrEx 60 AVOREN 60 Pharmacokinetic 60 ARCOXIA 60 Tipranavir 60 crizotinib PF # 60 ABCSG 60 BCIRG 60 relapsed MCL 60 DAVANAT R exhibits 60 Hormone Refractory Prostate Cancer 60 ENDEAVOR III 60 Metastatic Renal Cell Carcinoma 60 FDG-PET/CT 60 Arch Neurol 60 II Clinical Trial 60 Ameris Bancorp Reports 60 Capsules CII 60 Meets Primary Endpoint 60 Adjuvant Treatment 60 dosing cohorts 60 reduce serum phosphate 60 riociguat 60 TAXUS ATLAS 60 APTIVUS 60 Castration Resistant Prostate Cancer 60 Trial Evaluating 60 ToGA 60 coinfected patients 60 undetectable HBV DNA 60 treatment naive genotype 60 Clinical Trial Results 60 Clin Chem 60 IMPACT DCM 60 Safinamide 60 demonstrated clinically meaningful 60 CYT# potent vascular disrupting 60 canakinumab 60 subgroup analyzes 60 ORAL Sync 60 COMFORT II 60 Pivotal Phase III 60 Sipuleucel T 60 SABCS 60 PegIFN RBV 59 postintervention 59 solifenacin 59 mg/m2 cohort 59 SUCCEED trial 59 Septic Shock 59 Adalimumab 59 FOLPI 59 dose escalation phase 59 Phase #/#a trial 59 CALGB # [002] 59 icatibant 59 CaPre TM 59 CIMZIA TM 59 Prostate Lung Colorectal 59 Telik Announces 59 ritonavir boosted 59 Dose Escalation 59 antiretroviral naive 59 EGS# 59 Tiotropium 59 RE LY trial 59 Therapeutic Efficacy 59 teriflunomide 59 ASCO abstract 59 RIO Lipids 59 prucalopride 59 nonrandomized studies 59 multicenter placebo controlled 59 Aggressive Reduction 59 Stent Restenosis 59 LT NS# 59 HBeAg seroconversion 59 Daptomycin 59 PROSTVAC ® 59 SPIRIT FIRST 59 Golimumab 59 Adtegrity.com Reports 59 virologic response 59 Cytogenetic 59 Nesiritide 59 Prognostic Value 59 Tesmilifene 59 Immunomedics Announces 59 oral FTY# 59 serum phosphorous 59 #F FDG PET 59 -#.# log# copies mL 59 SYMMETRY trial 59 TMC# C# 59 Lipid Lowering Treatment 59 Cancer Incidence Mortality 59 XPEL Announces 59 oral diclofenac 59 Patients Receiving 59 Digital Mammographic Imaging 59 prospectively defined 59 Mg Uk 59 virological response 59 Ocrelizumab 59 Active Ulcerative Colitis 59 multicenter randomized controlled 59 Candesartan 59 CTAP# Capsules 59 NCCTG N# 59 Blind Placebo Controlled Trial 59 MERLIN TIMI 59 Multicenter Phase 59 Vaccine Protects Against 59 Achieves Primary Endpoint 59 RIO Diabetes 59 lumbar spine BMD 59 brivaracetam 59 Antitumor Activity 59 TOFUTTI Announces 59 Bivalirudin 59 fosbretabulin 59 Combination Treatment 59 Meta Analysis 59 Prospective Randomized Trial 59 Demonstrates Positive 59 exploratory endpoints 59 mRCC 59 bortezomib refractory 59 interferon gamma 1b 59 Peginterferon Alfa 2a 59 multicentre randomized 59 Study Evaluating 59 Pegylated Liposomal Doxorubicin 59 genotypic resistance 59 Antifungals 59 CLL8 59 Xelox 59 pharmacokinetic PK 59 mean ± SEM 59 Renal Cell Carcinoma 59 CYP#A# substrate 59 recurrent GBM 58 ongoing Phase 1b 58 Arch Surg 58 evaluable subjects 58 INVEGA ® 58 bazedoxifene conjugated estrogens 58 ASCO GI 58 Phase III Clinical Trial 58 Meta analyzes 58 rALLy 58 VADT 58 Insulin Glargine 58 Remission Maintenance 58 Hepatotoxicity 58 Randomized Study 58 F FDG PET 58 Advanced Melanoma 58 Arch Intern Med 58 randomized multicenter trial 58 Cardiac Resynchronization 58 dose escalation clinical 58 bone marrow reticulin deposition 58 Mg Usa 58 Placebo Controlled Study 58 recurrent glioblastoma multiforme 58 Adenoma Prevention 58 sustained virologic response 58 ARIXTRA R 58 selective modulator 58 Vicriviroc 58 Depression Study TADS 58 HBeAg 58 demonstrated antitumor activity 58 rALLy trial 58 asthma immunotherapeutic 58 Glucosamine Chondroitin Arthritis 58 Diabetic Macular Edema 58 ancrod 58 Phase 2a trial 58 Endometrial Cancer 58 PRECiSE 58 Subgroup Analysis 58 dose cohort 58 viral kinetics 58 PROSTVAC VF 58 PERSEUS 58 Betaferon R 58 SEISMIC Trial 58 ORAL Solo 58 Clinical Outcome 58 Ranolazine 58 Phase IIIb clinical 58 Rate ORR 58 FOREXYARD Daily Forex 58 CUSTOM III 58 Bioequivalence 58 Velcade bortezomib 58 Salix Pharmaceuticals Announces 58 Tyrosine Kinase Inhibitor 58 Phase IIb Trial 58 Screening Trial DMIST 58 MoxDuo TM IR 58 Efficacy Results 58 Clinical Antipsychotic Trials 58 Intervention Trial GAIT 58 Springer journal Naturwissenschaften 58 MAGE A3 ASCI 58 Cariprazine 58 Phase 1a clinical 58 ASCO Gastrointestinal Cancers Symposium 58 Intervention Effectiveness 58 Investigational Compound 58 iclaprim 58 Venous Thromboembolism 58 budesonide foam 58 EMPHASIS HF trial 58 Acta Scandinavica 58 Cardiac Biomarkers 58 Systemic Sclerosis 58 ENESTnd 58 heFH 58 NHANES III 58 number NCT# ClinicalTrials.gov 58 ATAC Arimidex Tamoxifen Alone 58 Survival Benefit 58 Improves Outcomes 58 Temsirolimus 58 chromium supplementation 58 EDARBI 58 Amrubicin 58 Double Blind Placebo 58 Dasatinib 58 PLCO trial 58 reboxetine 58 statin monotherapy 58 CR nPR 58 blinded randomized placebo controlled 58 hematological parameters 58 BioSante Pharmaceuticals Reports 58 Cervical Dysplasia 58 lumiliximab 58 Randomized Controlled Trials 58 AVN# Phase 58 Prospective Randomized 58 J Natl Cancer Inst 58 Localized Prostate Cancer 58 Randomized trials 58 journal Ophthalmology 58 PROSTVAC TM 58 Desvenlafaxine Succinate 58 Brief Psychiatric 58 HCV Protease Inhibitor 58 assessing T DM1 58 substudy 58 mg kg dose 58 Improves Survival 58 florbetaben 58 HER2 positive metastatic breast 58 Diabetologia 58 dosing cohort 57 Statistically Significant Improvement 57 randomized discontinuation trial 57 Gastric Cancer 57 AA Amyloidosis 57 Natalizumab 57 guanfacine extended release 57 hemagglutination inhibition HAI 57 placebo controlled studies 57 HER2 expression 57 landmark ATHENA 57 Subgroup analyzes 57 evaluating mipomersen 57 Statistically Significant 57 Phase 2a Trial 57 Phase IIa trial 57 Heterozygous Familial Hypercholesterolemia 57 mcg dose 57 Randomized Evaluation 57 Angiographic 57 circulating endothelial cells 57 Kaplan Meier curve 57 Teriparatide 57 MenACWY CRM 57 Pivotal Phase 57 #:#-# [029] 57 phase Ib 57 GetGoal Phase III 57 Spectrum Pharmaceuticals Announces 57 TG MV 57 evaluating Prochymal 57 Non inferiority 57 Multicenter Trial 57 Controlled Trial 57 Atomoxetine 57 Tanespimycin 57 sorafenib Nexavar 57 Randomized Clinical Trial 57 placebo controlled clinical trials 57 Teriflunomide 57 Edge STudy 57 VP# [004] 57 HIV HCV coinfected 57 Demonstrates Potent 57 HYVET 57 DOI #.#/art.# 57 multicentre prospective 57 Cholesterol Levels SPARCL 57 ATACAND 57 multicenter randomized placebo controlled 57 preclinical efficacy 57 specified secondary endpoints 57 intravascular hemolysis 57 HoFH 57 pharmacokinetic PK study 57 Sangamo BioSciences Announces 57 Wisconsin Sleep Cohort 57 ACCORD Lipid 57 ANCHOR trial 57 Topline Results 57 Secondary efficacy endpoints 57 Phase IIIb 57 HGS ETR2 57 Pirfenidone 57 viral kinetic 57 CIN2 + 57 EXPLORE Xa 57 Demonstrates Significant 57 Preclinical Study 57 neoadjuvant therapy 57 immunohistochemical analysis 57 PROTECT AF 57 Patients Treated With 57 Antihypertensive 57 Rosuvastatin 57 Interferon Beta 57 paclitaxel eluting stents 57 chest radiographs 57 LENALIDOMIDE 57 posttreatment 57 Histopathologic 57 Initiate Phase 57 NSABP C 57 Femara letrozole 57 Stenting Trial CREST 57 Anti Tumor Activity 57 Vildagliptin 57 XL# SAR# 57 Monotherapy 57 Coronary Artery Calcium 57 Randomized Clinical Trials 57 β blockers 57 Glufosfamide 57 RE LY 57 Randomised 57 Pivotal Study 57 Investigational Drug 57 Hematological Cancers 57 MEND CABG 57 metastatic castration resistant 57 Ophena TM 57 Free Survival PFS 57 virologic 57 Cystatin C 57 Functional Outcomes 57 Primary endpoints 57 RE MODEL 57 Carotid Revascularization Endarterectomy vs. 57 seroconverted 57 TO AVOID PREGNANCY WHILE 57 AACR Frontiers 57 NOXAFIL 57 CYP#A# CYP#D# 57 abacavir lamivudine 57 AGILECT ® 57 HBeAg + 57 INSPIRE Trial Phase III 57 Sentinel Lymph Node Biopsy 57 Phase Ib II 57 phase IIa 57 AEGR 57 Match Fixtures 57 phase IIb clinical 57 Randomized Trials 57 adjuvant tamoxifen 57 Critically Ill Patients 57 amalgam fillings mercury vapor 57 Malignant Glioma 57 ADVEXIN efficacy 57 mg/m2 dose 57 PASI scores 57 ZOLINZA 57 CombAT 57 randomized controlled multicenter 57 Phase III Trial 57 Previously Treated 57 Chronic Liver Disease 57 EDEMA3 57 pharmacokinetic studies 57 Aflibercept 57 Solid Tumors 57 Vaccine Immunology 57 Negative Symptoms 57 BEXXAR Therapeutic Regimen 57 oral ridaforolimus 57 #nd EORTC NCI 57 endoscopic remission 57 heavily pretreated 57 ENDEAVOR IV 57 ALLHAT 57 EmbraceAC 57 ANCOVA 57 Cardiotoxicity 57 Plus Ribavirin 57 Fondaparinux 57 phase IIb trial 57 abysmal Shaiken 57 ELACYT 57 Stent Thrombosis 57 Sustained Efficacy 57 Adjuvant Chemotherapy 57 MF# adjuvanted vaccine 57 MedlinePlus Bird Flu 57 drilling wireline logs 57 Generalized Anxiety Disorder 57 Phase IIb Clinical Trial 57 ASCO GU 57 oral methylnaltrexone 57 Hepatitis C Infection 57 ug dose 57 Benign Prostatic Hyperplasia 57 Phase Ib clinical 57 Randomized Controlled 56 Cervista HPV HR 56 placebo controlled trials 56 Romiplostim 56 confirmatory clinical 56 registrational Phase 56 plasma pharmacokinetics 56 YERVOY 56 #th Interscience Conference 56 spirometric 56 CATIE AD 56 baseline FEV 56 NEUVENGE 56 Demonstrates Efficacy 56 Protease Inhibitors 56 Forodesine HCl 56 Carotid Stenting 56 randomized multicenter Phase III 56 Showed Significant 56 Myocardial Infarction Study 56 Clinical Psychology Review 56 #-# Full Text 56 MADIT CRT trial 56 Prevalence Worldwide 56 active comparator 56 Valhi Reports 56 CAPACITY trials 56 Long Lesion 56 Thromboembolism 56 DOI #.#/hep.# 56 subcutaneous PRO 56 Overactive Bladder 56 Ambrisentan 56 randomized controlled Phase 56 AASLD Meeting 56 Progressive Multifocal Leukoencephalopathy 56 Antitumor 56 Hemodialysis Patients 56 PEGINTRON TM 56 Multicenter 56 Phase Ib study 56 FDA defined valvulopathy 56 Late Breaker 56 Initiated Phase 56 BlogPoll Ballot 56 antibody titer 56 Ambulatory Blood Pressure 56 lumiracoxib 56 J Immunol 56 arzoxifene 56 Tigecycline 56 Nicotine Vaccine 56 Dr. Gabriel Lasala 56 Glatiramer Acetate 56 Dose Finding 56 Arch Dermatol 56 Calcium Acetate 56 Ozarelix 56 By JENNIFER LEARN 56 preclinical pharmacokinetic 56 APTIVUS R 56 PROactive study 56 Postmenopausal Women 56 median survivals 56 Relieve Depression 56 PRE SURGE 56 Phase 2b monotherapy 56 Lupus Drug 56 Idenix Pharmaceuticals Reports 56 Renal Cell Carcinoma RCC 56 pharmacokinetic PK profile 56 Clinical Trial Data 56 Preclinical Models 56 echocardiographic parameters 56 CLIRS 56 gp# vaccine 56 Randomized Double Blind Placebo 56 PreCISe study 56 CALGB 56 #:#-# [033] 56 phase IIa clinical 56 Observational Study 56 HIV uninfected 56 Nebulized 56 CARE HF 56 AACR San Antonio 56 selenium supplementation 56 Tori Spelling Garage Sale 56 Phase III ALLEGRO 56 Microalbuminuria 56 Randomised Trial 56 #mg dosing group 56 randomized Phase III 56 AVADO 56 Complicated Skin 56 Improved Second Quarter 56 PROVENGE sipuleucel T 56 ROCKET AF 56 longitudinal observational study 56 Ovarian PLCO Cancer 56 antiviral efficacy 56 retrospective cohort 56 dual endothelin receptor antagonist 56 clevidipine 56 Sleep Disturbances 56 Chemotherapy Improves 56 tocilizumab 56 Drug Shows Promise 56 Paxil paroxetine 56 Faslodex 56 evaluating REVLIMID 56 Fungal Infections 56 EMPOWER ™ 56 Phase Ib IIa 56 Aortic Stenosis 56 Degarelix 56 pharmacokinetics PK 56 BENICAR HCT 56 Hematologic 56 trastuzumab emtansine T DM1 56 Aggressive Drug Evaluation 56 ARBITER 6 56 Currency Majors Technical 56 randomized blinded 56 NSX Releases 56 Improved Survival 56 Cites Positive 56 1mg 2mg 56 NATRECOR R 56 Ann Oncol 56 virologically suppressed 56 Multiple Ascending Dose 56 Severe Asthma 56 Decitabine 56 Multiple Myeloma Patients 56 Breast Cancer Recurrence 56 Metabolic Endocrinology 56 SLNB 56 BARI 2D 56 Cochrane Systematic Review 56 completely resected 56 Leukemias 56 forodesine 56 ADAGIO study 56 Taping Results SPOILERS 56 #mg/day [002] 56 meta regression 56 #:#-#,# CrossRef Medline [002] 56 EDEMA3 trial 56 Randomized Phase III 56 LymphoStat B belimumab 56 www.thelancet.com 56 fidaxomicin Phase 3 56 Inflammatory Arthritis 56 Phase III Clinical Trials 56 phase 2a 56 Enoxaparin 56 LOCF 56 Multicenter Randomized Double 56 Study AREDS 56 AirBoss Announces 56 randomized multicenter 56 Histological 56 Phase 2b study 56 poor metabolizers 56 sunitinib malate 56 secondary efficacy endpoint 56 virologic responses 56 evaluating Xcytrin 56 Secondary endpoints 56 Cognitive Function 56 Cholesterol Lowering Drug 56 Carfilzomib 56 NASDAQ CLDX 56 Uterine Cancer 56 Romidepsin 56 Carotid Endarterectomy 56 Univariate analysis 55 invasive aspergillosis 55 preterm newborns 55 Matrix Phase 2b 55 Gastrointestinal Cancers Symposium 55 Platelet counts 55 Serious adverse reactions 55 PACCE trial 55 Afatinib 55 Phase Ib Clinical Trial 55 Tezampanel 55 EDEMA4 55 postoperative chemotherapy 55 SORT OUT III 55 BMC Musculoskeletal Disorders 55 Prostate Cancer Progression 55 anti arrhythmic drug 55 velafermin 55 Rosiglitazone Evaluated 55 Phase III Pivotal Trial 55 statistically significant correlations 55 Zemplar Capsules 55 Levels Linked 55 Potent Antiviral Activity 55 Echocardiographic 55 Significantly Improved 55 OBPM 55 TASKi2 55 Orally Active 55 Hematological 55 ADVANCE PD 55 Solorel TM 55 olaparib 55 Bayer HealthCare Onyx Pharmaceuticals 55 Sorafenib HCC Assessment 55 DAS# CRP 55 logistic regression analyzes 55 Antiviral Activity 55 oxcarbazepine 55 Investigational Treatment 55 GAMMAGARD 55 Aliskiren 55 CRLX# 55 Cancer Immunology Immunotherapy 55 IMPACT IMmunotherapy 55 Vitro Activity 55 FOSRENOL ® 55 HOMA IR 55 Trandolapril 55 ORACLE MS 55 Sapacitabine 55 Dialysis Outcomes 55 journal Gynecologic Oncology 55 Pafuramidine 55 angiotensin analog 55 Arixtra ® 55 Calcium Vitamin D 55 ASCEND HF 55 Paliperidone ER 55 Combo Therapy 55 CHARM Added 55 Phase 1b clinical trials 55 placebo controlled clinical 55 Patency 55 Preterm Labor 55 Telintra 55 tumor histology 55 PLCO 55 Phase III ADT 55 Aromatase Inhibitors 55 trastuzumab DM1 T DM1 55 Mycophenolate Mofetil 55 QLT# 55 Treated Patients 55 NO# [002] 55 Randomised Study 55 Dietary Modification Trial 55 microalbumin test 55 metastatic HRPC 55 cediranib 55 antiangiogenic activity 55 inhibin B 55 serum leptin 55 4CMenB 55 LAB CGRP 55 Denufosol 55 Demonstrates Statistically Significant 55 Treatment Shows Promise 55 Nymox Reports 55 NCT# ClinicalTrials.gov 55 CYP#D# genotype 55 Study Demonstrates 55 ALISTA 55 Molecular Cancer 55 NEVO ™ 55 Autologous Stem Cell Transplantation 55 Phase III psoriasis 55 Urgent Intervention Triage 55 cannabinor 55 Demonstrates Sustained 55 Lowers Risk 55 Traficet EN 55 R lenalidomide 55 Is Well Tolerated 55 J Clin Oncol 55 CT Colonography Trial 55 CR CRu 55 ARIXTRA 55 EntreMed Presents 55 Veterinary Vaccines 55 tramiprosate Alzhemed TM 55 Bezielle 55 severe hypercholesterolemia 55 colesevelam HCl 55 SPIRIT IV 55 randomized Phase IIb 55 EINSTEIN DVT 55 WWE SmackDown Taping Results 55 Acute Decompensated Heart Failure 55 HuMax EGFr 55 Anti Tumor 55 Phase 2a clinical 55 intradialytic hypotension IDH 55 ASH Annual Meeting 55 REG1 Anticoagulation System 55 EVEREST II 55 Serious Adverse Events 55 Acute Myocardial Infarction 55 Reduces Mortality 55 limiting generalizability 55 microbiologically evaluable 55 Complications Trial 55 Muraglitazar 55 By EURSOC Two 55 progression TTP 55 Completes Patient Enrollment 55 mitoxantrone plus 55 aclidinium 55 LUX Lung 55 See WARNINGS 55 multicenter Phase 55 Diamyd r 55 Vancocin R 55 barbiturates benzodiazepines 55 Targretin capsules 55 Inflammatory Markers 55 ONTARGET 55 ASCO Annual Meeting 55 Unstable Angina 55 Relapsed Refractory 55 nonrandomized 55 Stent Implantation 55 Univariate 55 Study Showed 55 multivariate regression analysis 55 Rheumatoid Arthritis Patients 55 briakinumab 55 Patient Outcomes 55 Philadelphia Chromosome Positive 55 posttest 55 Selective Cardiac Myosin Activator 55 Primary Endpoint 55 multicenter randomized clinical 55 TRITON TIMI 55 Zenvia Phase III 55 Resistant Hypertension 55 Betaferon ® 55 Bone Metastases 55 BR.# 55 liver transplant recipients 55 Bifidobacterium infantis # 55 First Patient Enrolled 55 Dementia Related Psychosis 55 Recurrent Glioblastoma 55 Colorectal Cancers 55 UPLYSO 55 receiving SIMPONI 55 HuMax CD# 55 5 HT6 receptor 55 multicenter phase 55 Kaplan Meier method 55 Phase 1b trial 55 INCB# [001] 55 gadolinium enhancing lesions 55 cetuximab Erbitux 55 pharmacodynamic effects 55 midstage clinical 55 Drug Prevents 55 Radical Prostatectomy 55 GW# [003] 55 R rilonacept Injection 55 statistically significant efficacy 55 Raloxifene STAR 55 Operative mortality 55 Adherex Reports 55 virologic failure 55 Decompensated Heart Failure 55 GVAX AML 55 via intradermal injections 55 induced tumor regression 55 #:#-#,# [003] 55 hsCRP levels 55 Prognostic Significance 55 randomized Phase 2b 55 Androxal TM 55 Iron Overload 55 Lymphocytic 55 compound INCB# 55 Hypertensive Patients 55 BoNTA 55 Knee Osteoarthritis 55 Chronic HCV 55 Diabet Med 55 timepoint 55 CYPHER R Sirolimus eluting 55 receiving VELCADE 55 Pharmacologic 55 Dose Ranging 55 Outpatient Setting 55 journal Ambulatory Pediatrics 55 monoinfected patients 55 CTRC AACR San Antonio 55 Oral Anticoagulants 55 Dacogen injection 55 & Rheumatism journal 55 CAVEATS 55 alteplase 55 Aspergillus nidulans 55 postmenopausal osteoporotic women 55 HBV infections 55 journal Pharmacoepidemiology 55 Bone Mineral Density 55 seronegative 55 Gene Variation 54 iniparib 54 ENDEAVOR II 54 secondary efficacy endpoints 54 x denotes seeding 54 Tasigna prolongs 54 Endocrine Society #st 54 Osteoporosis Drugs 54 REMICADE ® 54 Ultrasensitive 54 ABSORB trial 54 Ischemic Stroke 54 Intervention Trial 54 Tumor Progression 54 Arch Pediatr Adolesc Med 54 Predictive Value 54 histopathological 54 AACR #nd Annual Meeting 54 ACI TIPI 54 covariance ANCOVA 54 Profitable Third Quarter 54 Advaxis Phase 54 Ziprasidone 54 Multicenter Randomized 54 neratinib 54 enzastaurin 54 HORIZONS AMI 54 Myelodysplastic Syndromes 54 Novel Mechanism 54 Poorly Controlled 54 Phase #/#a 54 Chemotherapeutic Agents 54 ELISpot 54 Intervention Effectiveness CATIE 54 Pemphigus Vulgaris 54 Eur J Endocrinol 54 Phase Ib 54 Celecoxib APC trial 54 journal Menopause 54 #:#-#,# CrossRef 54 Diabetic Foot Ulcer 54 Truvada tablets 54 Phase III VISTA 54 Data Suggest 54 prospective nonrandomized 54 attain statistical significance 54 Statin Drugs 54 Myelofibrosis 54 SIRT1 activators 54 BCX# 54 Vectical TM Ointment 54 Clinical Oncology Annual Meeting